Quick Contact

TOKYO, October 7, 2020 – FUJIFILM Corporation (President: Kenji Sukeno) is expanding its gene therapy offering with the addition of viral vector process development and GMP[1] manufacturing services at FUJIFILM Diosynth Biotechnologies in Tees Valley.

FUJIFILM Diosynth Biotechnologies’ viral vector process development laboratories in the UK will be online from spring 2021. The laboratories will be outfitted with state-of-the-art equipment to support upstream (suspension and adherent) processes, downstream processing and analytical development. The GMP manufacturing capabilities are expected to be available from autumn 2021 and will support bulk drug substance production of investigational drugs used in early-stage clinical trials.

“FUJIFILM Corporation is committed to supporting the creation of new therapies for our customers through the stable supply of high-quality viral vectors that have the potential to have a profound impact for patients around the world,” said Takatoshi Ishikawa, senior executive vice president, general manager of Bio CDMO Division, FUJIFILM Corporation. “This initial investment will lay the groundwork to further grow our manufacturing services for gene therapies in Europe.”

Fujifilm first established a viral vector and vaccine development and manufacturing offering in 2014 at its College Station, Texas site, and has continued to invest and expand its services to position FUJIFILM Diosynth Biotechnologies as the leading contract development and manufacturing organization (CDMO).

“As a treatment modality, gene therapy holds tremendous promise to revolutionize the way patients are treated. We are committed to supporting our partners in their efforts to bring new therapies to market,” said Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. “This investment for production of early-stage investigational viral vector products is aligned with Fujifilm’s long-term strategy to provide process development and manufacturing solutions for its gene therapy partners. We will continue to invest in process development and manufacturing for gene therapies to meet the needs of our clients and drive forward progress in new drug development, to offer new treatment options to patients.”

Posted on 8th October 2020